Welcome to our dedicated page for Inogen SEC filings (Ticker: INGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inogen SEC filings document a respiratory medical technology business that develops, manufactures, markets, sells, and rents respiratory products for homecare use. Results filings and annual proxy materials cover operating performance, executive compensation, director elections, board committees, equity plans, and stockholder voting matters.
Recent Form 8-K disclosures also record share repurchase authorization, leadership and compensatory arrangements, material governance agreements, and Regulation FD communications. The filing record ties these corporate actions to Inogen’s common stock, board oversight, and product portfolio in portable oxygen, airway clearance, stationary oxygen, and CPAP categories.
Inogen Inc executive Mary E. Wright, the VP and Chief Accounting Officer, reported several equity compensation transactions. On March 1, 2026, multiple restricted stock unit tranches, including 1,755, 2,750 and 3,001 units, were exercised or converted into common stock at no cash cost. She also received common stock grants of 1,500 and 1,351 shares, while 675, 520, 1,058 and 1,155 shares of common stock at $6.10 were withheld to cover tax liabilities on the vesting awards. A separate grant of 8,000 restricted stock units was awarded on February 27, 2026, with vesting over several years subject to continued service.
Inogen Inc executive Jennifer M. Yi Boyer reported multiple equity award events. On February 27, 2026, she received a grant of 32,500 restricted stock units, each representing one share of common stock. These units vest in three equal annual installments starting March 1, 2027, subject to continued service.
On March 1, 2026, restricted stock units previously granted fully vested or were earned based on 2025 financial performance, and were converted into common shares. In connection with these vestings, blocks of shares were withheld at $6.10 per share to cover tax liabilities. After these transactions, she directly owned 26,747 shares of Inogen common stock.
Inogen’s Chief Commercial Officer Gregoire Ramade reported equity compensation activity involving restricted stock units and common shares. On March 1, 2026, 13,005 restricted stock units were exercised into 13,005 shares of common stock, and 6,022 shares were withheld at $6.10 per share to cover tax liabilities linked to a vesting award.
On February 27, 2026, Ramade received a new grant of 20,000 restricted stock units, each representing one share of Inogen common stock. One-third of this grant is scheduled to vest on March 1, 2027, with the remaining units vesting in equal annual installments on the same date in subsequent years, subject to continued service.
Inogen Inc executive Kevin P. Smith reported multiple equity compensation transactions. On February 27, 2026, he received a grant of 35,000 restricted stock units (RSUs), each representing the right to receive one share of Inogen common stock, subject to multi-year vesting based on continued service.
On March 1, 2026, 14,005 RSUs were exercised into common stock at no cost, and he was also awarded 1,500 shares of common stock at $6.10 per share. To cover tax withholding related to vested RSUs, 6,276 shares of common stock were disposed of at $6.10 per share. After these transactions, he directly held 22,007 shares of common stock and a remaining RSU balance as reported.
Inogen Inc EVP, CFO & Treasurer Michael J. Bourque reported multiple equity transactions. He acquired common stock through the vesting and exercise of restricted stock units on March 1, 2026, along with additional stock awards, and had shares withheld to satisfy tax obligations.
Several restricted stock unit awards converted into common stock at a stated price of $6.10 per share for tax purposes, with disposals labeled as tax-withholding transactions rather than open-market sales. After these transactions, he directly held 94,596 shares of Inogen common stock and 39,000 restricted stock units, each unit representing a contingent right to one share.
Inogen Inc CEO and President Kevin Raymond Merrill Smith reported multiple equity award transactions. On February 27, 2026, he received a grant of 90,000 restricted stock units, each representing a contingent right to one Inogen common share. Subject to continued service, one-third vests on March 1, 2027, with additional one-third portions vesting annually on the same date in subsequent years.
On March 1, 2026, performance-based and time-based restricted stock units vested, leading to share acquisitions and related tax-withholding dispositions. Vested awards included 28,334 and 30,012 shares from restricted stock units earned for 2025 financial performance, plus common stock awards of 685 and 32,725 shares. To cover tax liabilities on these vestings, the company withheld 16,374, 13,700, and 14,511 shares of common stock.
Inogen, Inc. files its annual report describing a respiratory-focused medical technology business built around portable oxygen concentrators, the Simeox airway-clearance device, Voxi 5 stationary oxygen concentrators, and Aurora CPAP masks. The company targets chronic respiratory conditions such as COPD, bronchiectasis and obstructive sleep apnea.
In 2025, Inogen generated $209.8 million of revenue in the United States, with about 45.1% from business-to-business sales, 29.5% from direct-to-consumer sales, and 25.4% from direct-to-consumer rentals. Approximately 39.8% of total 2025 revenue came from outside the United States, sold through distributors and large house accounts in 70 countries.
The report highlights a strategic collaboration with Yuwell to distribute Voxi 5 and Aurora masks in the United States and certain Asian markets, and the 2023 acquisition of Physio‑Assist, which added Simeox and expanded into airway clearance. Rental revenue depends heavily on Medicare programs, which supplied 61.9% of 2025 rental revenue and 9.5% of total revenue. As of December 31, 2025, Inogen employed 753 people worldwide and emphasizes innovation, regulatory compliance, and clinical evidence to support adoption of its products.
Inogen, Inc. reported modest growth but sharply better profitability for 2025 and announced a new share repurchase program. Full-year 2025 revenue rose 3.9% to $348.7 million, driven by 18.4% growth in international sales, while U.S. sales and rentals declined.
Net loss narrowed to $22.7 million from $35.9 million, and adjusted EBITDA turned positive at $2.7 million versus a $9.5 million loss in 2024. Cash, marketable securities, and restricted cash totaled $120.9 million with no debt. The board authorized a share repurchase program of up to $30 million through December 31, 2027.
For 2026, Inogen expects revenue of $366–$373 million, about 6% growth at the midpoint, and remains focused on further adjusted EBITDA improvement. Management highlighted new product launches, a strong balance sheet, and a strategic collaboration in China as key supports for future growth.
Inogen, Inc. reported modest growth but sharply better profitability for 2025 and announced a new share repurchase program. Full-year 2025 revenue rose 3.9% to $348.7 million, driven by 18.4% growth in international sales, while U.S. sales and rentals declined.
Net loss narrowed to $22.7 million from $35.9 million, and adjusted EBITDA turned positive at $2.7 million versus a $9.5 million loss in 2024. Cash, marketable securities, and restricted cash totaled $120.9 million with no debt. The board authorized a share repurchase program of up to $30 million through December 31, 2027.
For 2026, Inogen expects revenue of $366–$373 million, about 6% growth at the midpoint, and remains focused on further adjusted EBITDA improvement. Management highlighted new product launches, a strong balance sheet, and a strategic collaboration in China as key supports for future growth.
Inogen, Inc. filed a current report to let investors know it has released preliminary, unaudited revenue results for its fourth quarter and full year ended December 31, 2025. The company communicated these figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. The filing emphasizes that the amounts are preliminary, have not been audited, and may change once the annual financial statements are completed, so they provide only a partial view of the company’s financial performance. Inogen also clarifies that the press release and related information are being furnished, not filed, which affects how they are treated under securities laws and in future SEC filings.
Inogen Inc's Chief Commercial Officer reports stock transactions linked to vesting restricted stock units. On December 1, 2025, the officer acquired 31,566 shares of common stock at an exercise price of $0 when a portion of a time-based restricted stock award vested. On the same day, 12,943 shares were withheld and disposed of at $6.95 per share to cover tax withholding obligations.
After these transactions, the officer directly owned 37,246 shares of Inogen common stock and held 31,565 restricted stock units. Each restricted stock unit represents the right to receive one share of Inogen common stock, with one-third of the units vesting on each anniversary of the December 1, 2023 vesting commencement date, subject to continued service.